The safety and efficacy of MK-4280 (favezelimab), a humanized IgG4 LAG-3 inhibitor, in combination with pembrolizumab in relapse/refractory HL to anti-PD-1 therapy, was evaluated in clinical trials (Table 1) (61). Here, LAG3 is linked to Hodgkins lymphoma.